Casdin Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Casdin Capital’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.5M	Hold	186,014	–	–	0.23%	34
2026 Q1	$3.06M	Buy	186,014 +100,000	+116%	+$1.91M	0.23%	32
2025 Q4	$1.35M	Hold	86,014	–	–	0.08%	34
2025 Q3	$637K	Hold	86,014	–	–	0.05%	29
2025 Q2	$388K	Hold	86,014	–	–	0.04%	32
2025 Q1	$399K	Hold	86,014	–	–	0.03%	41
2024 Q4	$597K	Hold	86,014	–	–	0.04%	37
2024 Q3	$456K	Sell	86,014 -175,000	-67%	-$883K	0.03%	33
2024 Q2	$976K	Sell	261,014 -249,868	-49%	-$1.27M	0.07%	35
2024 Q1	$3.6M	Hold	510,882	–	–	0.27%	30
2023 Q4	$2.89M	Hold	510,882	–	–	0.28%	32
2023 Q3	$2.45M	Hold	510,882	–	–	0.27%	34
2023 Q2	$3.5M	Hold	510,882	–	–	0.31%	32
2023 Q1	$3.98M	Hold	510,882	–	–	0.33%	34
2022 Q4	$3.89M	Hold	510,882	–	–	0.3%	40
2022 Q3	$4.17M	Hold	510,882	–	–	0.27%	29
2022 Q2	$4.94M	Sell	510,882 -450,000	-47%	-$4.52M	0.42%	29
2022 Q1	$13.5M	Hold	960,882	–	–	0.6%	31
2021 Q4	$19.6M	Sell	960,882 -1	-0%	-$21	0.55%	36
2021 Q3	$21.4M	Hold	960,883	–	–	0.53%	38
2021 Q2	$21.8M	Buy	+960,883	New	+$19.6M	0.55%	35

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Casdin Capital's GLUE Position: Q2 2026 in Review

Casdin Capital held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 186,014 shares worth $4.5M. The position accounts for 0.23% of the portfolio, ranked #34.

Casdin Capital first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. The position peaked at $21.8M in Q2 2021. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

Casdin Capital held 186,014 shares of Monte Rosa Therapeutics worth $4.5M as of Q2 2026.
Casdin Capital left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
Monte Rosa Therapeutics made up 0.23% of Casdin Capital's portfolio in Q2 2026, its #34 holding.
Casdin Capital first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
Casdin Capital's Monte Rosa Therapeutics position peaked at $21.8M in Q2 2021.
193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.